Chimeric Antigen Receptor T Cell therapy — known more succinctly as CAR T therapy — is a remarkable, emerging immunotherapy that leverages a cancer patient’s own immune system in fighting their cancer. Celgene is exploring this potentially game-changing cancer treatment through several clinical trials. In order to accommodate the expansion of those trials and in anticipation of the eventual commercialization of CAR T treatments, Celgene is developing a state-of-the-art immunotherapy facility in Summit, New Jersey. We’re looking for dedicated individuals to staff this facility — individuals who are meticulous, quality-focused, and share our commitment to the patients we serve.
How does CAR T work? In short, cancer cells are able to mask themselves from a patients’s T cells, which are the cells that fight and kill cancer cells in the body. Through CAR T therapy, a patient’s blood is drawn and the T cells are isolated and engineered to recognize a specific antigen (i.e., a protein) on the surface of the cancer cells. Those modified T cells are then reintroduced into the patient’s body where they can multiply naturally and once again recognize and target the specific cancer cells.
Explore the positions below to see how you might join our team in this exciting area for cancer treatment.